SomaLogic expands into China with groundbreaking Biostar Technology Limited Partnership
SomaLogic to deliver 7,000-plex SomaScan® Platform to researchers in attractive Chinese proteomics market
SHANGHAI and BOULDER, Colo., May 10, 2023 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in proteomics technology, announced today that Biostar Technology Limited will be the company’s first authorized site in China to offer the 7,000-plex SomaScan® Assay and provide SomaScan data to their customers.
“We are delighted to be partnering with SomaLogic to expand the company’s global reach in Asia by providing their next-generation proteomics offering and establishing the first SomaLogic authorized site in Shanghai,” said founding Chief Executive Officer of Biostar and AccuraMed Steven Qiu. “We believe this partnership with SomaLogic will enable customers in China to make use of the SomaScan Assay as a powerful tool to study the mechanisms underlying the physiological and pathological processes in disease areas like cardiovascular and liver diseases, cancer and diabetes.”
Founded in 2006, Biostar Technology Limited is a leading technology supplier in the field of life science and translational medicine in China where the company has more than 1,000 customers in academic research, biopharma, clinical translational and in vitro diagnostics. Biostar will now be the first in the nation to offer SomaLogic’s proteomics technology.
“China is an exciting market for proteomics with tremendous untapped growth potential for SomaLogic,” said SomaLogic Chief Executive Officer Adam Taich. “Researchers in China have long embraced the value of market leading technology and having Biostar Technology Limited as a trusted partner and authorized site for SomaLogic’s SomaScan Platform will now bring the power of our solution to this region.”
Biostar joins Molecular Genomics in Singapore and FonesLife in Japan as SomaLogic authorized sites in the APAC region. Group 42 Healthcare became the first SomaLogic authorized site in the Middle East earlier this year.
SomaLogic is catalyzing drug research and development and biomarker identification as a global leader in proteomics technology. With a single 55 microliter plasma or serum sample, SomaLogic can run 7,000 protein measurements, covering more than a third of the approximately 20,000 proteins in the human body and twice as many as other proteomic platforms. For more than 20 years we’ve supported pharmaceutical companies, and academic and contract research organizations who rely on our protein detection and analysis technologies to fuel drug, disease, and treatment discoveries in such areas as oncology, diabetes, and cardiovascular, liver and metabolic diseases. Find out more at www.somalogic.com and follow @somalogic on LinkedIn.
Forward Looking Statements Disclaimer
This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements, other than statements of historical fact included in this press release, regarding our strategy, future operations, financial position, estimated revenues, projections, prospects, plans and objectives of management are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “forecast,” “guidance,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “continue,” “will likely result,” “possible,” “potential,” “predict,” “pursue,” “target” and similar expressions, although not all forward-looking statements contain such identifying words. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements do not guarantee future performance and involve known and unknown risks, uncertainties and other factors. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including factors which are beyond SomaLogic’s control. You should carefully consider these risks and uncertainties, including, but not limited to, those factors described under Part I, Item 1A – “Risk Factors” in our Annual Report on Form 10-K and other filings we make with the Securities and Exchange Commission. These filings identify and address important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SomaLogic assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. The Company will not and does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.